ANGLE
Over the last six years ANGLE has worked towards, and received in 2022, US Food and Drug Administration (FDA) clearance for their Parsortix ® PC1 System for use with metastatic breast cancer (MBC) patients. This marks a significant achievement as the first ever FDA cleared product for harvesting circulating tumour cells from MBC patient blood samples for user-validated subsequent analysis. This creates new possibilities in the era of personalised cancer medicine, with the ability to repeat a non-invasive liquid biopsy to assess metastatic breast cancer.
